New Risk • Jul 26
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$4.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.4m free cash flow). Share price has been highly volatile over the past 3 months (47% average weekly change). Earnings have declined by 2.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (CA$746k revenue, or US$529k). Market cap is less than US$10m (CA$4.08m market cap, or US$2.89m). Reported Earnings • Jul 26
Second quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 2Q 2025) Second quarter 2026 results: CA$0.004 loss per share (improved from CA$0.006 loss in 2Q 2025). Revenue: CA$177.8k (up 202% from 2Q 2025). Net loss: CA$1.62m (loss narrowed 9.2% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Reported Earnings • May 01
First quarter 2026 earnings released: CA$0.005 loss per share (vs CA$0.003 loss in 1Q 2025) First quarter 2026 results: CA$0.005 loss per share (further deteriorated from CA$0.003 loss in 1Q 2025). Revenue: CA$237.1k (up 190% from 1Q 2025). Net loss: CA$1.32m (loss widened 61% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 31
Full year 2025 earnings released: CA$0.017 loss per share (vs CA$0.018 loss in FY 2024) Full year 2025 results: CA$0.017 loss per share. Revenue: CA$472.3k (down 24% from FY 2024). Net loss: CA$5.04m (loss widened 18% from FY 2024). New Risk • Mar 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 41% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (64% average weekly change). Earnings have declined by 6.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (CA$360k revenue, or US$263k). Market cap is less than US$10m (CA$4.07m market cap, or US$2.96m). Tillkännagivande • Mar 12
Psyched Wellness Ltd. announced that it expects to receive CAD 1.719307 million in funding from Gotham Green Partners, LLC and affiliates and or co-investors of Gotham Green Psyched Wellness Ltd. announced that it has entered into a non-binding term sheet with returning investors Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. pursuant to which the Company shall complete a non-brokered private placement and will issue 170,228,410 common shares and common share purchase warrants for aggregate gross proceeds of up to CAD 1,719,306.941 on March 11, 2026. The Offering will be led by Gotham Green, and it may include affiliates and/or co-investors of Gotham Green. The company will raise proceeds in two tranches of up to CAD 859,653.47 each, subject to closing conditions. The Offering will consist of issuances of Common Shares at a price of CAD 0.0101 per Common Share and Warrants at a price of CAD 0.005 per Warrant. Each Warrant will entitle the holder thereof to acquire one additional Common Share at a price of CAD 0.0051 per Additional Share at any time on or before the Warrant expiry date, set sixty (60) months following the applicable closing date. The Company has obtained approval from the Canadian Securities Exchange (the "CSE") to issue the Common Shares and Warrants at a price lower than CAD 0.05 as the Offering Price is above the volume weighted average trading price of the Common Shares on the CSE for the 20 trading day period ending March 10, 2026. The Offering will be offered for purchase and sale to investors in the United States on a private placement basis. The initial tranche is scheduled to close on or about March 18, 2026 (the "Tranche 1 Closing Date") for aggregate gross proceeds of CAD 859,653.47 (the "Initial Tranche"). Subject to the policies of the CSE, closing of the second and final tranche could be for up to CAD 859,653.47 ("Tranche 2"). The Investor Group has no obligation to fund Tranche 2, and may elect to complete Tranche 2 in whole or in part or not at all in the Investor Group's sole discretion. Additionally, the closing of Tranche 2 shall be subject to satisfactory completion of due diligence in the Investor Group's sole discretion. All securities issued under the Offering will be subject to a four month and one day hold period from the applicable closing date and applicable legends as required pursuant to the U.S. Securities Act. Closing of the Offering is subject to customary closing conditions, including the approval of the CSE. Tillkännagivande • Nov 27
Psyched Wellness Ltd. Launches Calmer Psyched Wellness Ltd. announced the launch of Calmer, a new product offering that delivers twice the potency of its product, Calm. The Company has also enhanced the flavour profile of Calm in both the 30 ml and 60 ml formats, reducing the mushroom taste while maintaining potency and consumer experience. The launch coincides with Psyched's Black Friday promotion, offering customers a 40% discount site-wide (excluding merch) through December 1, 2025. Reported Earnings • Oct 31
Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2024) Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.006 loss in 3Q 2024). Revenue: CA$145.3k (down 39% from 3Q 2024). Net loss: CA$1.18m (loss narrowed 27% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 27
Second quarter 2025 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 2Q 2024) Second quarter 2025 results: CA$0.006 loss per share (further deteriorated from CA$0.005 loss in 2Q 2024). Revenue: CA$59.0k (down 76% from 2Q 2024). Net loss: CA$1.78m (loss widened 37% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 10
AME Wellness Inc. Working with its Advisors, Zerkalo LLC Completes an Initial Pilot Run of New Dietary Supplement in Form of 4 oz Shot Psyched Wellness Ltd. announced that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch. Reported Earnings • Mar 30
Full year 2024 earnings released: CA$0.018 loss per share (vs CA$0.021 loss in FY 2023) Full year 2024 results: CA$0.018 loss per share. Revenue: CA$623.2k (up 94% from FY 2023). Net loss: CA$4.26m (loss widened 24% from FY 2023). Tillkännagivande • Mar 04
Psyched Wellness Ltd., Annual General Meeting, May 15, 2025 Psyched Wellness Ltd., Annual General Meeting, May 15, 2025. Tillkännagivande • Nov 27
Psyched Wellness Ltd. Announces Resignation of Harrison Aaron as Director Psyched Wellness Ltd. announced that Harrison Aaron, a nominee of Gotham Green Partners, LLC ("Gotham Green"), has resigned as a director of the Company effective November 22, 2024. New Risk • Aug 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m (CA$469k revenue, or US$340k). Market cap is less than US$10m (CA$13.0m market cap, or US$9.39m). Reported Earnings • Jul 30
Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2023) Second quarter 2024 results: CA$0.005 loss per share. Net loss: CA$1.30m (loss widened 65% from 2Q 2023). Reported Earnings • Apr 30
First quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in 1Q 2023) First quarter 2024 results: CA$0.003 loss per share (improved from CA$0.007 loss in 1Q 2023). Net loss: CA$689.4k (loss narrowed 32% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Janeen Stodulski was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Feb 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (CA$271k revenue, or US$202k). Market cap is less than US$10m (CA$9.35m market cap, or US$6.95m). New Risk • Sep 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 39% per year over the past 5 years. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (CA$179k revenue, or US$131k). Minor Risk Market cap is less than US$100m (CA$19.8m market cap, or US$14.5m). New Risk • Aug 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.4m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (CA$179k revenue, or US$134k). Market cap is less than US$10m (CA$10.2m market cap, or US$7.63m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Board Change • Jul 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Harrison Aaron was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jun 22
Psyched Wellness Ltd. Announces Board Changes Psyched Wellness Ltd. announced that Amanda Galbraith has resigned as a director of the Company effective June 19, 2023. The Company also announced that Harrison Aaron has been appointed as director effective June 19, 2023. Harrison Aaron: Mr. Aaron is a Principal at Santa Monica based investment firm Gotham Green Partners, LLC ("Gotham Green") having joined the firm in early 2019. During his time at Gotham Green, in addition to helping lead the firm's broader investment efforts, he co-founded cannabis e-commerce retail and delivery business Amuse.com (currently serving Los Angeles, the Bay Area, and Sacramento), as well as co-founding Sandland Sleep (SandlandSleep.com), nationwide seller of highly-effective natural sleep aids, and is currently serving on the boards of both companies, as well as serving on the boards of VIOLA Brands and Engin Sciences. Prior to his time at Gotham Green, from 2013 to 2019, he covered the consumer sector as a senior analyst on the investment team at NYC-based JANA Partners, a multi-billion-dollar hedge fund investing in companies undergoing, or with the potential to undergo, value-unlocking changes. Mr. Aaron began his career on Goldman Sachs' Hedge Fund Strategies and Cross Asset Sales teams from 2009-2013, after graduating magna cum laude and Phi Beta Kappa from Colgate University, with high honors in Mathematical Economics. New Risk • Jun 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$54k). Market cap is less than US$10m (CA$10.9m market cap, or US$8.25m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding). New Risk • Jun 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$11.5m (US$8.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$72k revenue, or US$54k). Market cap is less than US$10m (CA$11.5m market cap, or US$8.63m). Tillkännagivande • May 20
Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023 Psyched Wellness Ltd., Annual General Meeting, Jul 11, 2023. Tillkännagivande • Feb 03
Psyched Wellness Ltd. Adds New Bottle Size for Their Amanita Muscaria Extract Calm Psyched Wellness Ltd. announced that they will be launching a new larger bottle size for their proprietary Amanita Muscaria Extract (AME-1) product Calm, on February 28th 2023. The new size will provide customers with double the servings per bottle, in a 60ml package. Calm is the first legal Amanita Muscaria extract available for sale in the USA. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Independent Chairman Michael Nederhoff is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Jul 28
Psyched Wellness Ltd. Announces Findings from an Ongoing Study with the National Research Council of Canada Psyched Wellness Ltd. announced the preliminary data from tests completed by the National Research Council of Canada (NRC). One of the primary immune cells in the brain are the microglia, which facilitate neurodevelopment and neurodegeneration. Recent work investigated how AME-1 extract could modify microglial functions. Microglia respond to a variety of stimuli, including lipopolysaccharides found in the cell walls of bacteria (LPS), viral components (such as poly I:C nucleotides) and inflammatory cytokines such as tumor necrosis factor (TNF). In a recent study, researchers stimulated human microglial cells with LPS, poly I:C and TNF in the presence of AME-1 to determine if AME-1 could modify how microglia respond to these common stimulants. The researchers found that a specific nucleotide, poly I:C, caused the microglia to be more activated than normal and produce important immune mediators. This could potentially indicate that AME-1 boosts the antiviral immune response in the brain, perhaps protecting brain tissue from viral infection. AME-1 had no significant effect on how microglia respond to LPS and TNF. However, AME-1 potentiated poly I:C activation of microglial cells, resulting in greater production of the chemokine, IL-8. The chemokine IL-8 is a protein that attracts immune cells to the site of infection. Preliminary research has shown that this process may be mediated by AME-1 upregulation of the Toll-Like Receptor -3, which is the receptor that mediates microglial responses to poly I:C. Further experiments will examine how AME-1 upregulates TLR3 by microglial cells and how this could be contributing to the increased responses to poly I:C, which may contribute to the anti-viral immune response in the brain and thus reduce viral infection. This work is preliminary, and more work is needed to further investigate the potential benefits from the natural product AME-1. Psyched Wellness is launching its first AME-1 product, Calm, in the coming months. Calm is currently available for preorder. Tillkännagivande • Jul 20
Psyched Wellness Commences Preorders for Calm in Path to Commercialization of Proprietary Amanita Muscaria Extract Psyched Wellness Ltd. announced that it's proprietary Amanita Muscaria Extract (AME-1) is now available for preorder in the USA. The company offers consumers a unique opportunity to purchase a safe and legal extract of the mushroom that has been used for thousands of years by various groups around the world for its healing properties. Psyched has approval to sell in the United States via Self-GRAS (Generally Regarded as Safe) designation, which allows the company to sell its AME-1 products. The company plans to submit the application for AME-1 as an NDI (a New Dietary Ingredient) to the FDA this fall. The product, called Calm, facilitates rest within the body and mind, and does not require a prescription. This leaves the retail landscape open to many possibilities for distribution and listing potential. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Independent Chairman Michael Nederhoff is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Apr 27
Psyched Wellness Ltd. Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1 Psyched Wellness Ltd. announced the company KGK, a licensed CRO in Canada, has reported recent findings from the analysis of the intestinal epithelial immune receptor expression study performed in conjunction with the 90-day oral toxicity study with Amanita Muscaria Extract (AME- 1). The in vivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both of which are found on the surface of gut epithelial cells. The Toll-like receptors are an important family within the innate immune system and play a vital role in host-defense mechanisms against pathogens. The main function of TLRs is the ability to recognize numerous pathogens, thus activating the host-defense mechanism through the induction of antimicrobial activity. Dectin-1 is a cell surface pathogen recognition receptor that recognizes soluble and /or particulate forms of -1,3 or -1,6-glucans and, like Toll-like receptors, plays an important role in the host-defense mechanism as well. The recent results of the in vivo study showed only a modest increase in TLR-2 and Dectin-1 receptors, but this was not a significant finding. It could be interpreted that the challenge of continuous dosing of AME-1 resulted in maximal cell surface expression of TLR-2 and Dectin-1, thus seeing only a modest positive upregulation of cell surface membrane expression. However, the sustained upregulation of both TLR-2 and Dectin-1 receptors indicates innate immune mechanisms that were primed and maintained throughout the course of the 90-day oral study. Furthermore, there was no downregulation of either surface receptor type, nor was there any over priming or stimulating effect which would have negatively impacted the immune system through the production of pro-inflammatory cytokines. Tillkännagivande • Mar 31
Psyched Wellness Ltd. Unveils New Product Name and Visual Identity Elements Psyched Wellness Ltd. prepares for a Spring launch in the USA to meet consumer demand for ethically sourced, high-quality Amanita Muscaria products. Introduced as the company's flagship product, Psyched Wellness will begin using the brand name 'Calm' for its proprietary Amanita Muscaria extract. The product, which is being investigated as a sleep-aid, is said to induce feelings of relaxation and balance and should be taken prior to periods of rest or recovery. Tillkännagivande • Mar 10
Psyched Wellness Ltd. GARS Dossier Approve by Panel of Experts, Providing Green Light to Market Products in the United States Psyched Wellness Ltd. announced that an independent review panel of scientific experts has concluded that Psyched's key proprietary extract of Amanita Muscaria, AME-1, is Generally Recognized As Safe (GRAS) as a bulk ingredient. The successful GRAS certification allows Psyched to legally sell its AME-1 products in the United States and is a key milestone in execution of the Company's strategy. The panel of experts concluded that AME-1 is safe for a variety of finished conventional food products, including: For use in the general adult population (adults > 18 years), except pregnant women and lactating mothers. Beverage powders and ready-to-drink beverages at a maximum total daily serving size of 872.718 mg/person/day (containing 2.89 mg/person/day of Alkaloid Blend [AMAB]). AME-1 will be intended for inclusion in dietary supplements by the intended target population at a maximum daily serving of 880 mg/person/day (containing 2.917 mg/person/day of AMAB). The cumulative evaluating panel of scientific experts concluded that when added to food, AME-1 is GRAS. This important status means that AME-1 can be used in food with no safety concern and a cumulative maximum daily dosage in beverage powders and ready-to-drink beverages was determined. The evidence was collected from the recent toxicology studies confirming that AME-1 does not induce any organ-system toxicity at the proposed serving size, as well as scientific evidence demonstrating that the substance is safe under the conditions of the intended use. Tillkännagivande • Feb 04
Psyched Wellness Ltd. Announces Additional Positive Results from the 14-Day Oral Toxicity Study of AME-1 Psyched Wellness Ltd. reported additional positive findings from the preclinical 14-day oral toxicity study with Amanita Muscaria (AME-1), which was performed in conjunction with an analysis of its impact on gut epithelial cells. The invivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both found in gut epithelial cells, which playan important role in defensive immune system mechanisms against pathogens. The 14-day oral invivo study resulted in a dose-dependent increase in Toll-like-receptor-2 expression, while Dectin-1 did not have any change in cell surface expression under the same study conditions. The marginal increase of up to two-fold in the TLR-2 study suggests AME-1 could be a potential bioactive agent with possible immune-priming effects, which may be due to its ability to increase cell surface plasma membrane concentration content of TLR-2. Tillkännagivande • Jan 28
Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada Psyched Wellness Ltd. announced that the preliminary data from its study with the National Research Council of Canada (NRC) indicates that AME-1, the Company's key proprietary extract, holds anti-inflammatory properties. The study is examining the anti-inflammatory properties of the AME-1 extract from the Amanita Muscaria mushroom by studying the effects of the extract on mast cells, which are important inflammatory cells present in the skin, gut, brain, and lungs. Prior research performed by the NRC had already shown that AME-1 inhibited mast cell activation of histamine release. The continued research has verified that pre-treatment of human mast cells with AME-1 results in the decrease of the release of pro-inflammatory mediators such as inflammatory cytokines. Tillkännagivande • Jun 30
Psyched Wellness Commences Next Pre- Clinical Study on AME-1 Psyched Wellness Ltd. announce that the company and its CRO partner, KGK Science, has commenced the next preclinical study, a 90-day oral toxicity study of AME-1. This new study will examine the effects of Amanita Muscaria on rodents and will involve a repeated dose 90-day oral toxicity study of AME-1. It aims to provide information on the possible anatomical responses which may arise from repeated exposure over a period of time, covering post-weaning maturation and growth into adulthood of the test animals. The study will provide information on the major toxic effects, indicate target organs and the possibility of accumulation of test chemical, and can provide an estimate of a no-observed-adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure. Recent Insider Transactions • Apr 24
CEO & Director recently bought CA$126k worth of stock On the 19th of April, Jeffrey Stevens bought around 500k shares on-market at roughly CA$0.25 per share. This was the largest purchase by an insider in the last 3 months. Jeffrey has been a buyer over the last 12 months, purchasing a net total of CA$157k worth in shares. Tillkännagivande • Mar 17
Psyched Wellness Ltd. Announces Board Changes Psyched Wellness Ltd. announced that Janeen Stodulski has been appointed as a director of the Corporation. Psyched also announced that Chris Hazelton has resigned as a director of the Corporation. Janeen brings more than 30 years in diverse tax, financial, and business consulting experience to the table. She has gained extensive accounting experience through her senior roles in public practice, as a partner at MNP and Client Service Manager at Grant Thornton LLP as well as several board positions and C-suite roles in a variety of companies. Janeen extensive expertise allows her to provide outside the box strategies and solutions in addition to comprehensive accounting services. Recent Insider Transactions Derivative • Mar 10
Independent Director exercised options to buy CA$345k worth of stock. On the 5th of March, Christopher Hazelton exercised options to buy 750k shares at a strike price of around CA$0.10, costing a total of CA$75k. This transaction amounted to 833% of their direct individual holding at the time of the trade. Since June 2020, Christopher has owned 90.00k shares directly. Company insiders have collectively bought CA$145k more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Mar 04
Psyched Wellness Ltd. Provides Update on Pre-Clinical Trial of its Muscimol Extract AME-1 Psyched Wellness Ltd. announced the company has received the results from its Maximum Tolerated Dosage (MTD) study conducted by KGK Science, a licensed CRO in Canada. This study is the first set of thorough toxicology assessments on the company's Amanita Muscaria extract, AME-1. The MTD study summarizes the maximum tolerated dose and LD50 thresholds for AME-1. This significant set of information obtained permits for the next step of pre-clinical studies involving a 14- and 90-day oral toxicity to further identify a safe, effective dose for human consumption. Tillkännagivande • Feb 18
Psyched Wellness Ltd. announced that it has received CAD 6.603 million in funding On February 17, 2021, Psyched Wellness Ltd. (CNSX:PSYC) closed the transaction. The company issued an aggregate of 21,300,000 units for gross proceeds of CAD 6,603,000. Is New 90 Day High Low • Feb 17
New 90-day high: CA$0.64 The company is up 276% from its price of CA$0.17 on 18 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 16% over the same period. Tillkännagivande • Feb 05
Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol Psyched Wellness Ltd. announced study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation models. Is New 90 Day High Low • Jan 26
New 90-day high: CA$0.41 The company is up 200% from its price of CA$0.14 on 27 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period. Tillkännagivande • Jan 17
Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol Psyched Wellness Ltd. announced that it has completed the first step in identifying the medicinal potential of Muscimol for various mental and physical health issues. The research was led by Psyched Wellness's board member and head of the Company's scientific committee, Prof. David Nutt. Prof. Nutt is a is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways. The study was initiated to compile and review all the scientific papers discussing Muscimol in order to provide the scientific evidence to support the thesis of using Muscimol as a potential treatment for various mental and physical health issues. Tillkännagivande • Jan 08
Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol Psyched Wellness Ltd. announced that it has commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes via a nerve derived immunity and neuroprotective modulation models. The study will be led by Brian Tancowny and will focus on determining the effectiveness of the active compound muscimol from the Amanita Muscaria mushroom for its potential dual antioxidant and anti-inflammatory properties. This preliminary work will focus on determining the potential role in health promotion via modulation of oxidative stress and inflammation. The mushroom, Amanita Muscaria naturally contain high levels of the active compound muscimol. This study will look at the potential
neuroprotective effects of muscimol via neurotoxicity and immunomodulatory invitro cell - based models. Antioxidants have been shown to reduce the risk of many diseases (including heart disease and certain cancers). Antioxidants can scavenge free radicals from the body cells and prevent or reduce the impact of the damage caused by oxidation. The protective effect of antioxidants continues to be studied around the world. Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids, which affect the central nervous system to block pain signaling to
the brain. Opioids have led to increased substance abuse by over prescribing and addictions. Muscimol if shown to have anti inflammatory properties may lead to a more effective natural therapeutic for treating many conditions. Tillkännagivande • Dec 30
Psyched Wellness Ltd. Commences Research on Muscimol for Various Ailments Psyched Wellness Ltd. announced that it has commenced research on Muscimol for various ailments, with a focus on mental health issues. The research is led by Psyched Wellness's board member, Prof. David Nutt. Prof. Nutt is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways. The purpose of the research is to gather all the scientific papers surrounding Muscimol and its various ailments, in order to support using Muscimol for mental health issues. Tillkännagivande • Dec 18
Psyched Wellness Ltd. Completes its First Extraction of a Legal Psychedelic Derived from Amanita Muscaria Mushrooms Psyched Wellness Ltd. announced that it has successfully completed its first extraction of a legal psychedelic derived from Amanita Muscaria mushrooms. The scientific team sourced dried Amanita Muscaria Mushroom caps from five separate suppliers from different geographic regions around the world. The dried Amanita was extracted using the Company's proprietary extraction protocol and was then packaged and sent with samples of the raw materials to an independent lab. The lab will be testing the extract for the necessary and desired compounds with a goal of providing the Company with a report within 5-7 days. The report will allow Psyched to finalize the specifications for its product, a pure, natural, and safe for human consumption Amanita Muscaria extract. Tillkännagivande • Nov 27
Psyched Wellness Ltd. Appoints Kevin Feeney to the Advisory Board Psyched Wellness Ltd. announced that Kevin Feeney has joined the advisory board of the Company to work with the team on identifying novel uses for Muscimol, the psychoactive constituent of Amanita Muscaria. Kevin Feeney, PhD, JD, is a cultural anthropologist and lawyer currently working as a Program Director and Instructor in Interdisciplinary Studies - Social Sciences at Central Washington University. His primary research interests include examining legal and regulatory issues surrounding the religious and cultural use of psychoactive substances, with an emphasis on peyote and ayahuasca, and exploring modern and traditional uses of Amanita muscaria, with a specific focus on medicinal use and preparation practices. He has recently published an edited volume on Amanita muscaria (Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration) and has also been published in the International Journal of Drug Policy, Journal of Psychoactive Drugs, Human Organization, and Curare, among other books and journals. He is a current board member of Cactus Conservation Institute, which is dedicated to the study and preservation of vulnerable cacti and is also a member of Chacruna's Council for the Protection of Sacred Plants. Tillkännagivande • Nov 17
Psyched Wellness Ltd. Adds Professor David Nutt to the Board of Directors Psyched Wellness Ltd. announced that Professor David Nutt has increased his role and responsibilities with the Company by moving from an Advisory Board position to being a full member of the Board of Directors. David Nutt is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways. Tillkännagivande • Oct 27
Psyched Wellness Ltd. Announces appointment of Brian Towncany to the Advisory Board Psyched Wellness Ltd. announced that Brian Towncany has joined the advisory board to support the management team on the scientific side as the company progresses through the pre-clinical trials for Amanita Muscaria with CRO partner. Mr. Tancowny has over 25 years of experience in Research and Development with government, academic, and private sector partners. He has built and managed diverse research portfolios in animal and human health supplements, personal care products and medical therapeutics. He has led diverse research teams in creating new and innovative research projects that have bridged private and government collaborators with a particular focus on end-stage development and product marketing. Mr. Tancowny is presently a quality-assurance manager with an in-depth understanding of the challenges of operational issues in start-up companies to regulatory procedures and policies. 
